Drug Watch

Latest News

Lloyd Miller, MD, PhD: Delving Into JNJ-2113 Data for Plaque Psoriasis
Lloyd Miller, MD, PhD: Delving Into JNJ-2113 Data for Plaque Psoriasis

February 20th 2024

Miller, Vice President, Immunodermatology Disease Area Leader, Johnson & Johnson, spoke with Dermatology Times about recently published data supporting JNJ-2113's potential in this indication.

Lifileucel Receives FDA Accelerated Approval for Advanced Melanoma
Lifileucel Receives FDA Accelerated Approval for Advanced Melanoma

February 19th 2024

FDA Accepts Galderma’s BLA for Nemolizumab for the Treatment of Prurigo Nodularis and Atopic Dermatitis
FDA Accepts Galderma’s BLA for Nemolizumab for the Treatment of Prurigo Nodularis and Atopic Dermatitis

February 14th 2024

Dermavant Submits sNDA to FDA for Tapinarof Cream 1% to Treat AD Down to 2 Years
Dermavant Submits sNDA to FDA for Tapinarof Cream 1% to Treat AD Down to 2 Years

February 14th 2024

Targeted Oral Peptide JNJ-2113 Led to Significant PASI, IGA Responses in Phase 2b Trial for Plaque Psoriasis
Targeted Oral Peptide JNJ-2113 Led to Significant PASI, IGA Responses in Phase 2b Trial for Plaque Psoriasis

February 8th 2024

Video Interviews
Podcasts
The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics
The Cutaneous Connection

More News

© 2024 MJH Life Sciences

All rights reserved.